Investors Purchase Large Volume of Teva Pharmaceutical Industries Call Options (NYSE:TEVA)

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) saw unusually large options trading activity on Monday. Stock investors purchased 33,840 call options on the stock. This is an increase of 73% compared to the average volume of 19,561 call options.

Insider Activity at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, CEO Richard D. Francis sold 442,935 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $32.36, for a total value of $14,333,376.60. Following the transaction, the chief executive officer directly owned 642,099 shares in the company, valued at approximately $20,778,323.64. The trade was a 40.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Placid Jover sold 14,150 shares of the business’s stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $31.67, for a total value of $448,130.50. Following the completion of the transaction, the insider owned 6,774 shares in the company, valued at $214,532.58. This trade represents a 67.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 858,799 shares of company stock worth $28,185,035 in the last three months. Company insiders own 0.55% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in TEVA. Corient Private Wealth LLC increased its holdings in Teva Pharmaceutical Industries by 28.4% in the fourth quarter. Corient Private Wealth LLC now owns 49,063 shares of the company’s stock valued at $1,531,000 after buying an additional 10,843 shares in the last quarter. Dorsey Wright & Associates acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter valued at approximately $1,640,000. Compound Planning Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $323,000. Invesco Ltd. boosted its stake in shares of Teva Pharmaceutical Industries by 4.8% during the 4th quarter. Invesco Ltd. now owns 2,710,105 shares of the company’s stock worth $84,582,000 after acquiring an additional 124,304 shares in the last quarter. Finally, Alpine Woods Capital Investors LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter worth approximately $463,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Stock Up 3.2%

Teva Pharmaceutical Industries stock opened at $29.47 on Tuesday. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.04 and a quick ratio of 0.80. Teva Pharmaceutical Industries has a 1-year low of $12.47 and a 1-year high of $37.35. The company has a market cap of $33.88 billion, a PE ratio of 24.56, a price-to-earnings-growth ratio of 9.56 and a beta of 0.72. The stock’s 50 day moving average price is $32.88 and its 200 day moving average price is $26.82.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The firm had revenue of $4.71 billion during the quarter, compared to analysts’ expectations of $4.36 billion. During the same quarter in the prior year, the business posted $0.71 earnings per share. Teva Pharmaceutical Industries’s revenue was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, sell-side analysts predict that Teva Pharmaceutical Industries will post 2.5 EPS for the current fiscal year.

Wall Street Analyst Weigh In

TEVA has been the subject of several analyst reports. The Goldman Sachs Group upped their price target on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Bank of America lifted their price objective on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Barclays boosted their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a research note on Friday, January 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, January 21st. Finally, Piper Sandler restated an “overweight” rating and issued a $41.00 target price (up from $40.00) on shares of Teva Pharmaceutical Industries in a research note on Wednesday, March 4th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and an average price target of $37.67.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.